AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Down 8.5% in March

AngioDynamics, Inc. (NASDAQ:ANGO) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 2,250,000 shares, a decrease of 8.5% from the March 15th total of 2,460,000 shares. Based on an average daily trading volume, of 575,400 shares, the short-interest ratio is currently 3.9 days.

Analyst Ratings Changes

ANGO has been the subject of several recent research reports. Oppenheimer raised shares of AngioDynamics from a “market perform” rating to an “outperform” rating and set a $12.00 price target for the company in a research report on Friday, April 5th. HC Wainwright dropped their price target on shares of AngioDynamics from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Monday, January 8th. Finally, Raymond James dropped their price target on shares of AngioDynamics from $12.00 to $10.00 and set an “outperform” rating for the company in a research report on Tuesday, January 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, AngioDynamics currently has a consensus rating of “Moderate Buy” and an average target price of $14.25.

AngioDynamics Trading Up 3.2 %

NASDAQ ANGO opened at $6.51 on Wednesday. The firm has a market cap of $260.79 million, a price-to-earnings ratio of -1.35 and a beta of 0.66. The company has a 50 day moving average of $5.93 and a 200-day moving average of $6.46. AngioDynamics has a 1-year low of $5.26 and a 1-year high of $11.38.

Insider Activity

In related news, CEO James C. Clemmer acquired 10,000 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was acquired at an average price of $6.70 per share, with a total value of $67,000.00. Following the completion of the transaction, the chief executive officer now owns 539,066 shares of the company’s stock, valued at $3,611,742.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.10% of the stock is owned by company insiders.

Institutional Trading of AngioDynamics

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of AngioDynamics by 6.4% during the fourth quarter. Vanguard Group Inc. now owns 2,268,461 shares of the medical instruments supplier’s stock worth $17,785,000 after buying an additional 136,323 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of AngioDynamics by 19.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 30,951 shares of the medical instruments supplier’s stock worth $243,000 after buying an additional 5,131 shares in the last quarter. Public Employees Retirement System of Ohio increased its holdings in shares of AngioDynamics by 21.4% during the fourth quarter. Public Employees Retirement System of Ohio now owns 76,539 shares of the medical instruments supplier’s stock worth $600,000 after buying an additional 13,500 shares in the last quarter. Barclays PLC increased its holdings in shares of AngioDynamics by 131.3% during the fourth quarter. Barclays PLC now owns 88,263 shares of the medical instruments supplier’s stock worth $692,000 after buying an additional 50,108 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its stake in shares of AngioDynamics by 20.6% during the fourth quarter. Nuveen Asset Management LLC now owns 430,429 shares of the medical instruments supplier’s stock valued at $3,375,000 after purchasing an additional 73,397 shares during the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.